JP2021529813A5 - - Google Patents

Info

Publication number
JP2021529813A5
JP2021529813A5 JP2021500540A JP2021500540A JP2021529813A5 JP 2021529813 A5 JP2021529813 A5 JP 2021529813A5 JP 2021500540 A JP2021500540 A JP 2021500540A JP 2021500540 A JP2021500540 A JP 2021500540A JP 2021529813 A5 JP2021529813 A5 JP 2021529813A5
Authority
JP
Japan
Prior art keywords
disorders
disorder
formula
thiadiazine
dioxo
Prior art date
Application number
JP2021500540A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020012423A5 (https=
JP2021529813A (ja
JP7440486B2 (ja
Filing date
Publication date
Priority claimed from HUP1800249A external-priority patent/HU231414B1/hu
Application filed filed Critical
Publication of JP2021529813A publication Critical patent/JP2021529813A/ja
Publication of JP2021529813A5 publication Critical patent/JP2021529813A5/ja
Publication of JPWO2020012423A5 publication Critical patent/JPWO2020012423A5/ja
Priority to JP2024020524A priority Critical patent/JP2024056879A/ja
Application granted granted Critical
Publication of JP7440486B2 publication Critical patent/JP7440486B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021500540A 2018-07-13 2019-07-12 チアジアジン誘導体 Active JP7440486B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024020524A JP2024056879A (ja) 2018-07-13 2024-02-14 チアジアジン誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1800249 2018-07-13
HUP1800249A HU231414B1 (hu) 2018-07-13 2018-07-13 Tiadiazin származékok
PCT/IB2019/055949 WO2020012423A1 (en) 2018-07-13 2019-07-12 Thiadiazine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024020524A Division JP2024056879A (ja) 2018-07-13 2024-02-14 チアジアジン誘導体

Publications (4)

Publication Number Publication Date
JP2021529813A JP2021529813A (ja) 2021-11-04
JP2021529813A5 true JP2021529813A5 (https=) 2022-07-20
JPWO2020012423A5 JPWO2020012423A5 (https=) 2022-07-20
JP7440486B2 JP7440486B2 (ja) 2024-02-28

Family

ID=89992726

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021500540A Active JP7440486B2 (ja) 2018-07-13 2019-07-12 チアジアジン誘導体
JP2024020524A Withdrawn JP2024056879A (ja) 2018-07-13 2024-02-14 チアジアジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024020524A Withdrawn JP2024056879A (ja) 2018-07-13 2024-02-14 チアジアジン誘導体

Country Status (23)

Country Link
US (2) US12194050B2 (https=)
EP (1) EP3820865A1 (https=)
JP (2) JP7440486B2 (https=)
KR (1) KR20210033003A (https=)
CN (1) CN112424198A (https=)
AR (1) AR115783A1 (https=)
AU (1) AU2019300515B2 (https=)
BR (1) BR112020027016A2 (https=)
CA (1) CA3104264A1 (https=)
CL (1) CL2021000081A1 (https=)
CO (1) CO2021001224A2 (https=)
CU (1) CU24622B1 (https=)
EA (1) EA202190246A1 (https=)
GE (2) GEAP202215558A (https=)
HU (1) HU231414B1 (https=)
IL (1) IL279939B2 (https=)
MX (1) MX2021000461A (https=)
MY (1) MY207757A (https=)
PE (1) PE20210465A1 (https=)
PH (1) PH12021550007A1 (https=)
SG (1) SG11202012769QA (https=)
TW (1) TWI827628B (https=)
WO (1) WO2020012423A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103191A4 (en) * 2020-02-14 2024-03-06 University of Pittsburgh - of the Commonwealth System of Higher Education HEAT SHOCK PROTEIN MODULATORS AND THERAPEUTIC AGENTS FOR HUNTINGTON'S DISEASE
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
CN111454232B (zh) * 2020-05-30 2021-11-23 南方医科大学 一种1,3,4-噻二嗪类化合物及其应用
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016548A1 (ja) 2004-08-09 2006-02-16 Eisai R & D Management Co., Ltd. ヘテロ環化合物を含有する新規な抗マラリア剤
NZ566036A (en) 2005-09-13 2010-06-25 Janssen Pharmaceutica Nv 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor
ES2274729B1 (es) 2005-11-11 2008-06-01 Consejo Superior Investig. Cientificas Derivados de 5-carboxilato y 5-carboxamida 2-sustituidos de 1,1-dioxo-1,2,6-tiadiazina con propiedades cannabinoides.
US20100298314A1 (en) 2006-12-20 2010-11-25 Schering Corporation Novel jnk inhibitors
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
MX2010003156A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de aril amida substituida con tetrazol y usos de los mismos.
KR20100124272A (ko) 2008-02-07 2010-11-26 아보트 러보러터리즈 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법
AR070936A1 (es) 2008-03-19 2010-05-12 Janssen Pharmaceutica Nv 1,2,4 -triazoles trisustituidos
EP2110377A1 (en) 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
WO2009127678A1 (en) 2008-04-17 2009-10-22 Glaxo Group Limited Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
CA2725940A1 (en) 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
EP2488520B1 (en) * 2009-10-13 2015-09-02 Merck Sharp & Dohme B.V. Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor
EP3795573B1 (en) 2009-12-31 2022-07-06 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
WO2012042915A1 (en) 2010-10-01 2012-04-05 Raqualia Pharma Inc. Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists
SG192078A1 (en) * 2011-02-03 2013-08-30 Lupin Ltd Pyrrole derivatives used as modulators of alpha7 nachr
US9617210B2 (en) * 2013-03-13 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 NACHR modulators
AR107928A1 (es) * 2016-03-22 2018-06-28 Merck Sharp & Dohme Moduladores alostéricos de receptores de acetilcolina nicotínicos
US10870630B2 (en) 2016-11-01 2020-12-22 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
WO2018112204A1 (en) 2016-12-14 2018-06-21 Cephalon, Inc. Spiropiperidine derivatives
SG11201908012SA (en) 2017-03-02 2019-09-27 Assembly Biosciences Inc Cyclic sulfamide compounds and methods of using same
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok

Similar Documents

Publication Publication Date Title
JP2021529813A5 (https=)
JP2021531260A5 (https=)
JP5487214B2 (ja) キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
JP7094989B2 (ja) シクロプロピルウレアホルミルペプチド2受容体およびホルミルペプチド1受容体アゴニスト
JP2016510032A5 (https=)
JP6387411B2 (ja) Alx受容体アゴニストとしてのベンゾイミダゾリル−メチル尿素誘導体
JP7599411B2 (ja) 受容体相互作用タンパク質キナーゼ1阻害剤(ripk1)としての1h-インダゾールカルボキサミド
JP7434294B2 (ja) キナーゼ阻害剤としてのインダゾールカルボキサミド
JP6618525B2 (ja) ピラゾール類
JP2011528372A (ja) α7ニコチン性アセチルコリンレセプターインヒビター
JP4198989B2 (ja) セロトニン作動性薬
JP2011512400A (ja) 2−アザ−ビシクロ[2.2.1]ヘプタン誘導体
JP2010507619A (ja) オキサジアゾール及びチアジアゾール化合物並びにニコチン性アセチルコリン受容体調節物質としてのその使用
JP2006022108A5 (https=)
JP2010534647A (ja) 2−アザ−ビシクロ[3.3.0]オクタン誘導体
JP2008539195A (ja) 新規のオキサジアゾール誘導体及びそれらの医学的使用
JP2008500336A (ja) 治療化合物:骨格としてのピリジン
CN1166173A (zh) 对σ和/或5HTIA受体具备活性的四氢吡啶-(或4-羟基哌啶)烷基吡咯
RS55927B1 (sr) Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova primena kao lek
JP2024056879A (ja) チアジアジン誘導体
JP2008517042A (ja) 2−アミド−4−フェニルチアゾール誘導体、その調製及び治療的使用
JP2017526661A (ja) Taarリガンドとしての置換アゼチジン誘導体
JP2006503062A5 (https=)
CN104411709B (zh) 可用作阿尔茨海默病的诊断剂的咪唑并[2,1]噻唑-3-酮衍生物
JP2020502213A5 (https=)